Live Analyst Rating Changes 31643 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Stephen Brozak
WBB

Stephen Brozak

WBB Securities
Wall Street Analyst
★☆☆☆☆
#3052
on 13Foresight · ranked by our own returns
33%
Success Rate
-24.0%
Average Return
3 of 9 calls profitable · +4.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 33% of Stephen Brozak's ratings turned a profit when each position was held for 1 year — averaging -24.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

8 Buy 0 Hold 0 Sell
Stephen's Stock Coverage 17 ratings · 2026-09-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
VOGX
Vogenx, Inc.
 Sep 02, 2026 BUY Strong Buy
+28.3% avg upside
1 analyst
$42.00
28.34% Upside
 · ·
SRPT
Sarepta Therapeutics
 Mar 26, 2026 BUY Buy
+191.8% avg upside
49 analysts
$38.00
85.72% Upside
 +3.8% ·
OMER
Omeros
 Jan 08, 2026 BUY Buy
+13.9% avg upside
14 analysts
$55.00
200.84% Upside
 +40.9% ·
CELU
Celularity
 Sep 09, 2025 BUY Buy
+987.4% avg upside
6 analysts
$6.00
325.47% Upside
 -25.7% ·
MRKR
Marker Therapeutics
 Mar 31, 2025 BUY Strong Buy
+1165.7% avg upside
9 analysts
$12.50
986.93% Upside
 +5.7% ·
ARCT
Arcturus Therapeutics
 Jun 30, 2024 BUY Buy
+105.3% avg upside
36 analysts
$25.00
69.82% Upside
 -45.0% ·
CFRXQ
ContraFect
 Jun 08, 2022 BUY Buy
+10969999900.0% avg upside
10 analysts
$560.00
55999999899.97% Upside
 · ·
RDHL
RedHill Biopharma
 May 28, 2021 BUY Strong Buy
+3001.3% avg upside
7 analysts
$16.00
2381.08% Upside
 · ·
LSTA
Lisata Therapeutics
 May 14, 2019 BUY Buy
+694.5% avg upside
11 analysts
$6.80
317.25% Upside
 -43.5% ·
SCYX
SCYNEXIS
 Apr 18, 2019 BUY Strong Buy
+165.1% avg upside
10 analysts
$8.00
65.26% Upside
 · ·
ADMA
ADMA Biologics
 Apr 04, 2019 BUY Strong Buy
+18.6% avg upside
15 analysts
$11.50
24.67% Upside
 -40.5% ·
TTOO
T2 Biosystems
 Mar 08, 2019 BUY Buy
+710525.0% avg upside
10 analysts
$20.00
1999899.91% Upside
 · ·
ATHXQ
Athersys
 Oct 04, 2018 BUY Buy
+2996428471.4% avg upside
8 analysts
$9.00
899999899.92% Upside
 · ·
CLDX
Celldex
 Dec 06, 2017 BUY Strong Buy
+9.7% avg upside
28 analysts
$10.00
72.82% Downside
 -90.6% ·
CTSO
Cytosorbents
 Oct 29, 2015 BUY Strong Buy
+85.4% avg upside
13 analysts
$13.00
102.74% Upside
 -21.5% ·
LIVN
LivaNova
 May 10, 2011 BUY Strong Buy
+2.9% avg upside
15 analysts
 — · ·
CNSY
Cerenome
 Jan 08, 2010 BUY Strong Buy
+1280.8% avg upside
11 analysts
 — · ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Stephen Brozak — Frequently Asked Questions
How accurate are Stephen Brozak's stock ratings?
Based on the calls 13Foresight could measure, about 33% of Stephen's ratings were profitable over a one-year hold, with an average return of -24.0% per rating, or +3.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Stephen ranked on 13Foresight?
Stephen Brozak is currently ranked #3052 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Stephen cover?
Stephen most recently has ratings on VOGX, SRPT, OMER, CELU, MRKR, ARCT, CFRXQ, RDHL, LSTA, SCYX, ADMA, TTOO and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.